ARCHIVES

The Impact of Triple Calamities: Flat Funding, the End of ARRA, and a Dramatic Loss of Purchasing Power

This article is from The Cancer Letter archive.

Vol. 40 No. 41 | October 31, 2014

Download PDF Visit The Full Archive

Related Articles

FDA Committee Okays Leuprolide NDA, But Recommends Against Mitoxantrne, Epirubicin

April 5, 1985

Cancer Program Critic Epstein Invited To NCAB T Make Argument: “We’re Losing War In Cancer”

May 1, 1992

Without Advisor’s Input, Healy Approves Protocol For Gene Therapy

January 15, 1993

In Brief: After Nickles Removes Block, Senate Confirms Oncologist Henney As FDA Commissioner

October 23, 1998

Multivitamin Use Doesn’t Impact Outcomes, Study Finds

September 24, 2010

DCPC To Merge Two Programs, Reorganizes Chemoprevention

November 4, 1994